Abstract: The present invention provides a method of treating squamous histology cancers, breast cancer, prostate cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, and colorectal cancer in a patient comprising administering to a patient in need of such treatment an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof; in combination with an effective amount of a compound of the formula: or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a method of treating squamous histology cancers and PI3K pathway activated large cell lung and colorectal cancers in a patient comprising administering to a patient in need of such treatment an effective amount of 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one, or a pharmaceutically acceptable salt thereof; in combination with an effective amount of necitumumab.

Abstract: The present invention provides a combination therapy comprising the compound 4-[4-[4-(4-fluoro-3-trifluoromethyl-phenyl)-1-methyl-1H-imidazol-2-yl]-piperidin-1-yl]-1H-pyrazolo[3,4-d]pyrimidine, or a pharmaceutically acceptable salt thereof, and an mTOR inhibitor for use in the treatment of glioblastoma multiforme, adenocarcinomas of the colon, non-small-cell lung cancer, small-cell lung cancer, cisplatin-resistant small-cell lung cancer, ovarian cancer, leukemia, pancreatic cancer, prostate cancer, mammary carcinoma, renal cell carcimoma, multiple myeloma, Kaposis Sarcoma, Hodgkins lymphoma, lymphangioleiomyomatosis, Non-Hodgkins lymphoma or sarcoma.